Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>BOCI Elevates SINO BIOPHARM's TP to HKD8.7; Rating Kept Buy
Recommend 11 Positive 28 Negative 5 |
||||
|
||||
|
SINO BIOPHARM (01177.HK)'s 1H25 revenue increased by 10.7% YoY, in line with expectations, primarily driven by strong sales of innovative drugs and biosimilars, as well as a recovery in generic drug sales, BOCI released a research report noting. Meanwhile, a YoY surge of 140% in the company's net profit from continuing operations is likely supported by dividend income and changes in financial assets. Management maintained guidance for double-digit growth in 2025, expecting to receive a USD300 million milestone payment from Merck in 2H25 and potential BD licensing deals. BOCI raised its target price for SINO BIOPHARM from HKD7.7 to HKD8.7 and kept the Buy rating unchanged. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
